May 20, 2026
This is the first in a five-part series on the science and methodology behind clinical practice guidelines and consensus statements. The series “From Hippocrates to...
Read More
May 12, 2026
On April 2, 2026, the U.S. Food and Drug Administration issued a warning letter to a Michigan-based manufacturer of drug products called Purolea Cosmetics Lab....
Read More
May 5, 2026
Here’s a pattern I’ve seen repeatedly. A medical affairs team builds a publication plan. Timelines align to a congress deadline. Authors are confirmed. A solid...
Read More
April 21, 2026
On March 30, 2026, I attended RISE Together: Data Sharing Across the Rare Disease Ecosystem [1] expecting a discussion about the platforms and infrastructure needed...
Read More
April 10, 2026
On March 25, 2026, I attended MAX: Medical Affairs eXcellence Forum, Canada’s first forum dedicated entirely to medical affairs in biopharma. Organized by Agilis Health...
Read More